ArticleSeminars in oncology2013
Therapy-related myelodysplasia and acute myeloid leukemia.
Article in Seminars in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 217 citations in OpenAlex.
- FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.Blood advances · 2021Trial
- Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.Blood advances · 2020Trial
- Trial
- Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Causes of excess nonlymphoma death in 58 000 patients with DLBCL diagnosed during 1997 to 2020 and followed for up to 25 years.Blood advances · 2026Article
- Exposure to Agent Orange and association with myelodysplastic syndromes.Blood advances · 2026Article
- Article
- Myelodysplasia From Valproic Acid Resolved by Cessation.Case reports in hematology · 2026Article
- Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer.Frontiers in oncology · 2026Article
- Relationship between specific microRNA expression and radioresistant conditions in HL60 acute myeloid leukemia cells.Molecular medicine reports · 2025Article
- The long-term effects of chemotherapy on normal blood cells.Nature genetics · 2025Article
- Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors.Current oncology (Toronto, Ont.) · 2025Review
- Late effects of the treatment of childhood cancer.World journal of clinical cases · 2025Article
- Abnormalities in Chromosomes 5 and 7 in Myelodysplastic Syndrome and Acute Myeloid Leukemia.Annals of laboratory medicine · 2025Review
- Childhood Cancer Survivorship Care in Limited Resource Settings: A Narrative Review and Strategies to Promote Global Health Equity.JCO global oncology · 2025Review
- Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes.Current hematologic malignancy reports · 2025Review
- Late subsequent leukemia after childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).Cancer medicine · 2024Article
- Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.IJU case reports · 2024Article
- Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.Blood advances · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Therapy-related leukemia (myelodysplasia and acute myeloid leukemia-t-MDS/AML) is a well-known complication of conventional chemoradiotherapy used to treat a variety of primary malignancies including Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), sarcoma, and ovarian and testicular cancers. The median time to development of t-MDS/AML is 3-5 years, with the risk decreasing markedly after the first decade. t-MDS/AML is the major cause of non-relapse mortality after autologous hematopoietic cell transplantation (HCT) for HL or NHL. The magnitude of risk of t-MDS/AML is higher, and the latency is shorter after HCT, compared to conventional therapy. Two types of t-MDS/AML are recognized depending on the causative therapeutic exposure: an alkylating agent/radiation-related type and a topoisomerase II inhibitor-related type. Inter-individual variability in the risk for development of t-MDS/AML suggests a role for genetic variation in susceptibility to genotoxic exposures. Treatment of t-MDS/AML with conventional therapy is associated with a uniformly poor prognosis, with a median survival of 6 months. Because of the poor response to conventional chemotherapy, allogeneic HCT is recommended. Current research is focused on developing risk prediction and risk reduction strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.